Effect of SGLT2 inhibitor, canagliflozin, for the size of lipid particles
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000020027
- Lead Sponsor
- Tokyo Medical and Dental University Department of Medical Genetics / Gerontorgy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) History of hypersensitivity of canagliflozin 2) Severe ketosis, diabetic coma or precoma 3) Severe infection, pre or post surgery, or severe trauma 4) Patients taking fibrate-based medicines or pioglitazone 5) Patients taking diuretic medicines 6) eGFR < 45 mL/min/1.73 m2 or artificial dialysis 7) Considered as inadequate by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of the data of 20 lipoproteins fractions measured by high-performance gel permeation chromatography at 3 months after canagliflozin administration
- Secondary Outcome Measures
Name Time Method 1) Change of hemoglobin A1c (HbA1c) for 3 months at 3 months after canagliflozin administration 2) Change of body mass and body mass index (BMI) at 3 months after canagliflozin administration 3) Change of blood biochemical value at 3 months after canagliflozin administration